Document is current
Any future updates will be listed below
-
Authors
Berg, Kathryn
Dockrell, Dervil
Colvin, Lesley
Fraser, William D
Tang, Jonathan CY
Aspray, Terry
Dennison, Elaine
Divyateja, Hrushikesh
Ghouri, Nazim
Hanison, Esther
Keen, Richard
McCloskey, Eugene
O’Neill, Terence W
Rahman, Faizanur
Siddiqi, Mashood
Tuck, Stephen
Turton, Jane
Ralston, Stuart H https://orcid.org/0000-0002-2804-7586
-
Funding
Funding for this research was provided by:
Paget's Association
H2020 European Research Council (787270)
- License Information
-
More Information
Article History
Received: 5 June 2024
Accepted: 20 August 2024
First Online: 30 September 2024
Declarations
:
: William D Fraser reports funding to his institution from Novartis, Takeda, NPS Pharma, Sanofi, Amolyt and Entera-Bio Pharma outside the submitted work and donation of assay materials and evaluation kits from Abbot Diagnostics outside the submitted work; Jonathan C Y Tang reports participating in advisory boards for NPS Pharma, Amolyt and Entera-Biopharma; having received assay materials from Abbott Diagnostics; having received funding to his institution from Novartis, Takeda, NPS Pharma and Sanofi; and honoraria from Novartis, Sanofi and Ascendis outside the submitted work. Eugene McCloskey reports receiving honoraria from Amgen, Thornton & Ross and Flynn Pharma outside the submitted work. Stuart H Ralston reports funding to his institution from Kyowa Kirin, UCB, and the Royal Osteoporosis Society outside the submitted work. The remaining authors have no conflicts of interest to report.
: This research was conducted with the approval of the West of Scotland Research Ethics Committee 3 (18/WS/0236) and all participants gave written informed consent prior to taking part.
: The study did not involve experimental animals.
